![]() ![]() Its flagship product is the Molegro Virtual Docker, which is a platform for predicting protein-ligand interactions. The company currently offers four products for drug discovery. Molegro opened its doors in 2005, with funding from unnamed investors to commercialize algorithms developed by Thomsen during his days as a doctoral student at Aarhus University. It also shifts the burden of providing software support to the shoulders of a much larger team at CLC Bio, freeing Molegro’s employees to focus on software development, Gorlitz said. Other advantages of the acquisition include access to a much larger client base and more development resources as well as a presence in the North American market, Thomsen told BioInform. Molegro was an appealing target because it offers “really high-quality software that we think meets our standards," Gorlitz said, adding that CLC will also benefit from bringing Molegro's developers on board.įor Molegro, it “allows us to become part of a strong analysis platform and focus even more on developing the next generation of molecular docking products," René Thomsen, the company’s CEO, said in a statement. “The idea is to start building from both ends and then eventually we’ll have something that is coherent across the whole spectrum.”ĭeveloping these types of tools in house would have taken a great deal of time, so CLC opted to buy rather than build. “Right now, we are really focused on next-generation sequencing and is in a different area of the spectrum of molecular analysis with a focus on proteins and ligands … it's some distance away from the core of our current product portfolio,” he said. Lasse Gorlitz, CLC Bio’s vice president of communications, told BioInform that the purchase aligns with the company's strategy to provide tools that encompass all aspects of molecular analysis. Under the terms of the acquisition, all existing Molegro customers with active support and software upgrade contracts have been transferred to CLC Bio and all of Molegro’s staff are relocating to CLC Bio’s headquarters. The acquisition expands CLC's portfolio beyond its existing fleet of NGS analysis software - which includes CLC Genomics Workbench and Genomics Server -to add tools for molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activity against receptors, and determination of molecule similarity. Both firms are privately held and based in Aarhus, Denmark. The purchase, announced this week, marks the first acquisition for CLC Bio. Stepping away from its focus on sequence analysis, CLC Bio officially threw its hat into the drug discovery software ring with its acquisition of Molegro, a developer of molecular modeling software. Advances in Clinical Genomics Profiling. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |